Home » Posts tagged with » Dave Johnson
Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]

VelosBio begins phase 2 trial of VLS-101 in solid tumors

VelosBio, a San Diego-based biopharma company, said that it has dosed the first patient in a phase 2 clinical trial of its investigational antibody-drug conjugate (ADC) VLS-101 in patients having solid tumors. VLS-101, which is the company’s lead product candidate, targets a cell-surface protein called ROR1. Expressed during embryofetal development, ROR1 is however not seen […]

Continue reading …
Alliqua to acquire San Francisco-based biopharma company Adynxx

Alliqua acquisition of Adynxx : Pennsylvania-based Alliqua BioMedical has agreed to merge with San Francisco-based biopharma company Adynxx to form a clinical-stage pharmaceutical firm focused on development of disease-modifying, non-opioid therapies for the treatment of pain. As per the merger terms, Adynxx stockholders will become the majority holders of Alliqua’s outstanding common stock on a […]

Continue reading …